Real-world Study for Patients With Advanced Hepatobiliary Tumors

Inclusion Criteria: Subjects must meet all of the following criteria： 1. ≥18 years old, gender is not limited, and life expectancy is at least 6 months. 2. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the American Association for the Study of Liver Diseases or standard for the diagnosis and treatment of primary liver cancer 2017 in China). 3. The Barcelona staging classification: class B-C. 4. Child-Pugh classification: class A-B. 5. At least one measurable lesion (RECIST v1.1) 6. Unable to perform radical surgery or patient refuse surgery. 7. Subjects need palliative treatment, and have received or are undergoing any of the following three treatments: * Monotherapy or combination therapy with targeted drug associated with genetic variation in the subject. * Or, treat with pan-target anti-vascular drugs, such as sorafenib, regorafenib, lenvatinib, apatinib. * Or, immunotherapy or immunotherapy combined with targeted therapy or (and) classical chemotherapy. 8. Subjects volunteer to participate in the study and sign informed consent. Exclusion Criteria: Patients with one or more of the following criteria should be excluded: 1. Patients with early hepatobiliary tumor. 2. The Barcelona staging classification: class A. 3. Child-Pugh classification: class C. 4. Radical surgical resection. 5. CT or MRI shows unclear tumor boundary or no measurable lesions (RECIST v1.1). 6. Drug abuse, or any medical, psychological, or social condition that may affect the study, patient compliance, or even compromise the safety of the patient. 7. Conduct other experimental drug treatments other than this test within 4 weeks before the start of the study; or participate in another clinical study that has an impact on the results of this study. 8. Mental or medical instability makes patients unable or unwilling to sign informed consent. 9. Patients after comprehensive assessment are considered by the investigators to be unsuitable for participating in the study.